Cargando…

Risk assessment tools for QT prolonging pharmacotherapy in older adults: a systematic review

PURPOSE: Many drugs are associated with the risk of QT prolongation and torsades de pointes (TdP), and different risk assessment tools (RATs) are developed to help clinicians to manage related risk. The aim of this systematic review was to summarize the evidence of different RATs for QT prolonging p...

Descripción completa

Detalles Bibliográficos
Autores principales: Skullbacka, Simone, Airaksinen, Marja, Puustinen, Juha, Toivo, Terhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005415/
https://www.ncbi.nlm.nih.gov/pubmed/35156131
http://dx.doi.org/10.1007/s00228-022-03285-3
_version_ 1784686455045488640
author Skullbacka, Simone
Airaksinen, Marja
Puustinen, Juha
Toivo, Terhi
author_facet Skullbacka, Simone
Airaksinen, Marja
Puustinen, Juha
Toivo, Terhi
author_sort Skullbacka, Simone
collection PubMed
description PURPOSE: Many drugs are associated with the risk of QT prolongation and torsades de pointes (TdP), and different risk assessment tools (RATs) are developed to help clinicians to manage related risk. The aim of this systematic review was to summarize the evidence of different RATs for QT prolonging pharmacotherapy. METHODS: A systematic review was conducted using PubMed and Scopus databases. Studies concerning risk assessment tools for QT prolonging pharmacotherapy, including older adults, were included. Screening and selection of the studies, data extraction, and risk of bias assessment were undertaken. RESULTS: A total of 21 studies were included, involving different risk assessment tools. Most commonly used tools were risk scores (n = 9), computerized physician order entry systems (n = 3), and clinical decision support systems (n = 6). The tools were developed mainly for physicians and pharmacists. Risk scores included a high number of risk factors, both pharmacological and non-pharmacological, for QT prolongation and TdP. The inclusion of patients’ risk factors in computerized physician order entry and clinical decision support systems varied. CONCLUSION: Most of the risk assessment tools for QT prolonging pharmacotherapy give a comprehensive overview of patient-specific risks of QT prolongation and TdP and reduce modifiable risk factors and actual events. The risk assessment tools could be better adapted to different health information systems to help in clinical decision-making. Further studies on clinical validation of risk assessment tools with randomized controlled trials are needed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00228-022-03285-3.
format Online
Article
Text
id pubmed-9005415
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-90054152022-04-14 Risk assessment tools for QT prolonging pharmacotherapy in older adults: a systematic review Skullbacka, Simone Airaksinen, Marja Puustinen, Juha Toivo, Terhi Eur J Clin Pharmacol Review PURPOSE: Many drugs are associated with the risk of QT prolongation and torsades de pointes (TdP), and different risk assessment tools (RATs) are developed to help clinicians to manage related risk. The aim of this systematic review was to summarize the evidence of different RATs for QT prolonging pharmacotherapy. METHODS: A systematic review was conducted using PubMed and Scopus databases. Studies concerning risk assessment tools for QT prolonging pharmacotherapy, including older adults, were included. Screening and selection of the studies, data extraction, and risk of bias assessment were undertaken. RESULTS: A total of 21 studies were included, involving different risk assessment tools. Most commonly used tools were risk scores (n = 9), computerized physician order entry systems (n = 3), and clinical decision support systems (n = 6). The tools were developed mainly for physicians and pharmacists. Risk scores included a high number of risk factors, both pharmacological and non-pharmacological, for QT prolongation and TdP. The inclusion of patients’ risk factors in computerized physician order entry and clinical decision support systems varied. CONCLUSION: Most of the risk assessment tools for QT prolonging pharmacotherapy give a comprehensive overview of patient-specific risks of QT prolongation and TdP and reduce modifiable risk factors and actual events. The risk assessment tools could be better adapted to different health information systems to help in clinical decision-making. Further studies on clinical validation of risk assessment tools with randomized controlled trials are needed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00228-022-03285-3. Springer Berlin Heidelberg 2022-02-14 2022 /pmc/articles/PMC9005415/ /pubmed/35156131 http://dx.doi.org/10.1007/s00228-022-03285-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Skullbacka, Simone
Airaksinen, Marja
Puustinen, Juha
Toivo, Terhi
Risk assessment tools for QT prolonging pharmacotherapy in older adults: a systematic review
title Risk assessment tools for QT prolonging pharmacotherapy in older adults: a systematic review
title_full Risk assessment tools for QT prolonging pharmacotherapy in older adults: a systematic review
title_fullStr Risk assessment tools for QT prolonging pharmacotherapy in older adults: a systematic review
title_full_unstemmed Risk assessment tools for QT prolonging pharmacotherapy in older adults: a systematic review
title_short Risk assessment tools for QT prolonging pharmacotherapy in older adults: a systematic review
title_sort risk assessment tools for qt prolonging pharmacotherapy in older adults: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005415/
https://www.ncbi.nlm.nih.gov/pubmed/35156131
http://dx.doi.org/10.1007/s00228-022-03285-3
work_keys_str_mv AT skullbackasimone riskassessmenttoolsforqtprolongingpharmacotherapyinolderadultsasystematicreview
AT airaksinenmarja riskassessmenttoolsforqtprolongingpharmacotherapyinolderadultsasystematicreview
AT puustinenjuha riskassessmenttoolsforqtprolongingpharmacotherapyinolderadultsasystematicreview
AT toivoterhi riskassessmenttoolsforqtprolongingpharmacotherapyinolderadultsasystematicreview